InProTher

InProTher is a biotechnology startup founded in 2018, dedicated to creating cutting-edge cancer immunotherapies. The company's slogan, "InProTher is creating advanced cancer immunotherapies based on pre-clinical models with Professor Holst," succinctly captures its mission. With a focus on pioneering cancer immunotherapies, InProTher has shown promising pre-clinical results in animal models, where the immunotherapies not only eliminated tumors but also induced immunity to reoccurring cancers.

This success was further enhanced when combined with immune checkpoint inhibitors, leading to pronounced effects in animal models. The research driving InProTher's work leverages the expertise of Associate Professor Peter Johannes Holst and his team, as well as international collaborators.

The company has recently received a significant boost through a €6.00M Seed Round investment on 24 May 2023, with funding from The European Innovation Council and SeedFolio. InProTher's focus on leveraging pre-clinical success and its collaboration with renowned experts make it a compelling prospect in the biotechnology and healthcare industries.